Gustav Roussy
Veracyte, Gustave Roussy Partner to Study Biology of Metastatic Tumors
Veracyte will use its multiomic platform to analyze tumor samples and data from Gustave Roussy and build a biomarker database for precision drug development.
ASCO Data Bolster Talzenna, Xtandi Benefit in HRR-Mutant mCRPC as Pfizer Pursues Allcomers Approval
Premium
Biomarker-selected patients benefited from the added PARP inhibitor, but oncologists still don't know what to think about the benefit in patients without HRR mutations.
EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment
Premium
A new analysis from the Phase II APPLE trial showed minimal differences in overall survival, though the newer generation TKI significantly reduced brain metastases.
Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis
Premium
The WIN Consortium has further validated its DDPP algorithm in a recently published study and shown for the first time that biomarkers gleaned from normal tissue can be clinically informative, too.
LXRepair, Gustave Roussy Ink Research Partnership in Personalized Radiotherapy
The French biotech and cancer center have launched a joint lab to advance LXRepair's DNA-based functional assays to predict patients' responses to radiation.